Version May 2024
| Criterion | RECIST v1.1 | irRC | imRECIST |
| Tumor burden | Unidimensional | Bidimensional per WHO | Unidimensional, with other target lesion criteria (number, measurability) per RECIST v1.1 |
| Up to five target lesions or two per organ | Up to 10 target lesions or five per organ | ||
| New lesions | Always represent PD | New lesions do not categorically define PD | New lesions do not categorically define PD |
| Measurable new lesions incorporated into the total tumor burden | Measurable new lesions incorporated into the total tumor burden | ||
| Nonmeasurable new lesions preclude CR | Nonmeasurable new lesions preclude CR | ||
| Nontarget lesions | Can contribute to defining CR or PD (unequivocal progression) | Nontarget progression does not define PD | Nontarget progression does not define PD |
| Can only contribute to defining CR (complete disappearance required) | Can only contribute to defining CR (complete disappearance required) | ||
| PD | ≥20% increase in the SLD (RECIST) and ≥5 mm increase compared with nadir, unequivocal progression in nontarget lesions, and/or appearance of new lesions | Determined only on the basis of measurable disease | Determined only on the basis of measurable disease |
| Negated by subsequent non-PD assessment ≥4 weeks from the date first documented (lack of confirmation) | Negated by subsequent non-PD assessment ≥4 weeks from the date first documented (lack of confirmation) | ||
| ≥25% increase in the SLD compared with baseline/nadir | ≥20% increase in SLD (RECIST) compared with baseline/nadir | ||
| Confirmation of PD not required | Best response may occur before confirmed PD | Best response may occur after any number of PD assessments |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
